Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA.
Center for Metabolic Disease Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
J Expo Sci Environ Epidemiol. 2023 Mar;33(2):264-272. doi: 10.1038/s41370-022-00478-x. Epub 2022 Sep 16.
Phthalate exposure in pregnancy is typically estimated using maternal urinary phthalate metabolite levels. Our aim was to evaluate the association of urinary and placental tissue phthalates, and to explore the role of maternal and pregnancy characteristics that may bias estimates.
Fifty pregnancies were selected from the CANDLE Study, recruited from 2006 to 2011 in Tennessee. Linear models were used to estimate associations of urinary phthalates (2, 3 trimesters) and placental tissue phthalates (birth). Potential confounders and modifiers were evaluated in categories: temporality (time between urine and placenta sample), fetal sex, demographics, social advantage, reproductive history, medication use, nutrition and adiposity. Molar and quantile normalized phthalates were calculated to facilitate comparison of placental and urinary levels.
Metabolites detectable in >80% of both urine and placental samples were MEP, MnBP, MBzP, MECPP, MEOHP, MEHHP, and MEHP. MEP was most abundant in urine (geometric mean [GM] 7.00 ×10 nmol/l) and in placental tissue (GM 2.56 ×10 nmol/l). MEHP was the least abundant in urine (GM 5.32 ×10 nmol/l) and second most abundant in placental tissue (2.04 ×10 nmol/l). In aggregate, MEHP differed the most between urine and placenta (2.21 log units), and MEHHP differed the least (0.07 log units). MECPP was positively associated between urine and placenta (regression coefficient: 0.31 95% CI 0.09, 0.53). Other urine-placenta metabolite associations were modified by measures of social advantage, reproductive history, medication use, and adiposity.
Phthalates were ubiquitous in 50 full-term placental samples, as has already been shown in maternal urine. MEP and MEHP were the most abundant. Measurement and comparison of urinary and placental phthalates can advance knowledge on phthalate toxicity in pregnancy and provide insight into the validity and accuracy of relying on maternal urinary concentrations to estimate placental exposures.
This is the first report of correlations/associations of urinary and placental tissue phthalates in human pregnancy. Epidemiologists have relied exclusively on maternal urinary phthalate metabolite concentrations to assess exposures in pregnant women and risk to their fetuses. Even though it has not yet been confirmed empirically, it is widely assumed that urinary concentrations are strongly and positively correlated with placental and fetal levels. Our data suggest that may not be the case, and these associations may vary by phthalate metabolite and associations may be modified by measures of social advantage, reproductive history, medication use, and adiposity.
孕期邻苯二甲酸酯暴露通常通过母体尿液中邻苯二甲酸酯代谢物水平来估计。我们的目的是评估尿液和胎盘组织中邻苯二甲酸酯的相关性,并探讨可能会影响估计结果的母体和妊娠特征。
从 2006 年至 2011 年在田纳西州招募的 CANDLE 研究中选择了 50 例妊娠。线性模型用于估计尿液(2、3 个孕期)和胎盘组织(出生时)中邻苯二甲酸酯的相关性。在以下类别中评估了潜在的混杂因素和修饰因素:时间性(尿液和胎盘样本之间的时间间隔)、胎儿性别、人口统计学特征、社会优势、生殖史、药物使用、营养和肥胖。计算摩尔和分位数归一化的邻苯二甲酸酯,以方便比较胎盘和尿液水平。
80%的尿液和胎盘样本中均可检测到 MEP、MnBP、MBzP、MECPP、MEOHP、MEHHP 和 MEHP。MEP 在尿液中含量最丰富(几何平均值[GM] 7.00×10 nmol/L),在胎盘组织中含量第二丰富(GM 2.56×10 nmol/L)。MEHP 在尿液中含量最少(GM 5.32×10 nmol/L),在胎盘组织中含量第二少(2.04×10 nmol/L)。总体而言,MEHP 在尿液和胎盘之间的差异最大(2.21 个对数单位),而 MEHHP 的差异最小(0.07 个对数单位)。MECPP 在尿液和胎盘之间呈正相关(回归系数:0.31,95%置信区间:0.09,0.53)。其他尿液-胎盘代谢物的相关性受到社会优势、生殖史、药物使用和肥胖的修饰。
50 例足月胎盘样本中普遍存在邻苯二甲酸酯,正如之前在母体尿液中发现的一样。MEP 和 MEHP 的含量最丰富。测量和比较尿液和胎盘的邻苯二甲酸酯可以增进对妊娠期间邻苯二甲酸酯毒性的认识,并深入了解依赖母体尿液浓度来估计胎盘暴露的有效性和准确性。
这是首次报告人类妊娠中尿液和胎盘组织中邻苯二甲酸酯的相关性/关联。流行病学家仅依赖于母体尿液中邻苯二甲酸酯代谢物浓度来评估孕妇的暴露情况及其对胎儿的风险。尽管这尚未得到经验证实,但人们普遍认为,尿液浓度与胎盘和胎儿水平呈强正相关。我们的数据表明情况可能并非如此,并且这些相关性可能因邻苯二甲酸酯代谢物而异,并且可能受到社会优势、生殖史、药物使用和肥胖的修饰。